Hologic (NASDAQ:HOLX) Stock Rating Lowered by Argus

Hologic (NASDAQ:HOLX) was downgraded by equities research analysts at Argus from a “buy” rating to a “hold” rating in a research note issued on Monday,Finviz reports.

HOLX has been the topic of a number of other reports. BTIG Research restated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Evercore ISI downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Raymond James Financial lowered Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, BNP Paribas downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Three investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.29.

Hologic Price Performance

Shares of HOLX stock opened at $74.87 on Monday. The company has a market capitalization of $16.69 billion, a PE ratio of 30.19, a price-to-earnings-growth ratio of 2.12 and a beta of 0.69. The firm has a fifty day simple moving average of $74.64 and a 200-day simple moving average of $69.89. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. Hologic has a twelve month low of $51.90 and a twelve month high of $75.34.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the business earned $1.01 EPS. Hologic’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Hologic by 10.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares during the last quarter. Empowered Funds LLC boosted its stake in Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after purchasing an additional 3,790 shares during the period. Inspire Investing LLC grew its holdings in Hologic by 41.5% in the 1st quarter. Inspire Investing LLC now owns 5,075 shares of the medical equipment provider’s stock valued at $313,000 after buying an additional 1,488 shares during the last quarter. Parallel Advisors LLC increased its position in Hologic by 177.2% in the 2nd quarter. Parallel Advisors LLC now owns 2,708 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 1,731 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Hologic by 80.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,760 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 782 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.